Yung‐Shuan Lin

Yung‐Shuan Lin

Auto-generated profile, based on publicly available information

Yung‐Shuan Lin

Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
YLYung‐Shuan Lin
Yung‐Shuan Lin
HKHyuk Sung Kwon
Hyuk Sung Kwon
Wei-Ju LeeWei-Ju Lee
Wei-Ju Lee
MHMina Hwang
Mina Hwang
JJJee Hyang Jeong
Jee Hyang Jeong
JFJong‐Ling Fuh
Jong‐Ling Fuh
INTRODUCTION: Plasma phosphorylated tau (p‐tau) biomarkers have improved Alzheimer's disease (AD) diagnosis, but data from diverse Asian populations are limited. This study evaluated plasma p‐tau217 and p‐tau181 levels in Korean and Taiwanese populations. METHODS: All participants ( n = 270) underwent amyloid positron emission tomography (PET) and blood tests. Plasma p‐tau model‐derived probabilities of amyloid PET positivity (amyloid beta [Aβ]+) classified participants into low‐, intermediate‐, or high‐risk groups. RESULTS: In both cohorts, plasma p‐tau217 outperformed p‐tau181, especially in cognitively unimpaired participants (area under the curve = 0.921 [p‐tau217] vs. 0.769 [p‐tau181], P difference  = 0.022). Including apolipoprotein E status and glial fibrillary acidic protein improved model fit. The negative predictive value of the low‐risk group and positive predictive value of the high‐risk group were 97.5% and 86.0%, respectively. DISCUSSION: Plasma p‐tau217 and p‐tau181 effectively predict Aβ+ among culturally different Asian populations. P‐tau217 performed better, especially in the early stages of AD. Plasma p‐tau217–based models reduced intermediate‐risk classifications, suggesting fewer amyloid PET scans needed to confirm the diagnosis. Highlights: The efficacy of plasma phosphorylated tau (p‐tau)217 and p‐tau181 was analyzed in two Asian populations. Plasma p‐tau217 performs better in predicting amyloid positron emission tomography positivity, especially in cognitively unimpaired subjects. Adding apolipoprotein E and glial fibrillary acidic protein to p‐tau improved model accuracy. The models from each cohort were confirmed in the other cohort. Plasma p‐tau–based risk stratification may reduce the need for confirmatory tests.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
YLYung‐Shuan Lin
Yung‐Shuan Lin
Background: Plasma levels of phosphorylated tau 181 (p‐tau181) is one of the potential blood‐based biomarkers for the diagnosis of Alzheimer’s disease (AD). However, the association among plasma p‐tau181 and cognitive progression and structural brain change still needs to be investigated.Method: AD and mild cognitive impairment (MCI) patients diagnosed with a multidisciplinary consensus meeting were recruited. Cognitive function was assessed at baseline and at annual follow‐ups. Plasma p‐tau181 levels at baseline were measured using Quanterix SIMOA kits. The regional cortical thickness and volumes of baseline brain MRI were measured using the FreeSurfer image analysis suite. T‐tests and multiple regression were used for analyses. FDR tests were performed for multiple comparisons.Result: A total of 162 AD and 19 MCI patients were recruited (mean age = 77.4 ± 7.3 years, 42% male, 37% APOE ɛ4 carrier, and mean MMSE = 20 ± 5.4). There were 137 patients (75.7%) having at least two annual follow‐up and the mean follow‐up time was 2.1 ± 0.4 years. The baseline plasma p‐tau181 levels were correlated with the rates of MMSE decline per year (r = 0.284, p < 0.001). After adjusting for age, gender, education, APOE ɛ4 status and baseline MMSE, the baseline plasma p‐tau181 levels were still correlated with the yearly MMSE decline (β = 0.292, p = 0.001) and was able to predict MMSE decline>3 per year (OR = 4.03, 95% CI 1.47–11.05). There were 152 patients (135 AD and 17 MCI) with valid brain MRI. The cross‐sectional analyses with adjustments of age, gender, education and APOE ɛ4 status showed significant association between plasma p‐tau181 levels and left hippocampus volume (β = ‐0.205, p = 0.010), right hippocampus volume (β = ‐0.213, p = 0.009) and right middle temporal thickness (β = ‐0.292, p < 0.001).Conclusion: Higher plasma p‐tau181 levels were associated with the faster rate of MMSE decline in AD and MCI patients as well as the decreased volume and cortical thickness of several AD‐specific brain areas. Our study suggested that the plasma p‐tau181 could be a potential biomarker for tracking cognitive decline and reflecting structural brain changes in AD and MCI patients.

21 October 2026 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
YLYung-Shuan Lin
Yung-Shuan Lin
MTMeng-Ju Tsai
Meng-Ju Tsai
CLChien-Liang Lai
Chien-Liang Lai
HHHsiang-Ling Ho
Hsiang-Ling Ho
JFJong-Ling Fuh
Jong-Ling Fuh
Background Fully automated plasma p-tau217 assays may facilitate clinical implementation of blood-based testing for Alzheimer’s disease (AD) amyloid pathology. However, data on assay-specific decision thresholds and clinical utility in East Asian memory-clinic populations remain limited. Methods We evaluated plasma Roche p-tau217 in 139 participants from a Taiwanese memory clinic using amyloid PET or CSF biomarkers as reference standards. Diagnostic performance and single- and dual-cutoff decision thresholds were assessed. Head-to-head comparisons with Simoa p-tau217, Roche p-tau181, and neurofilament light chain (NfL) were performed in participants with complete biomarker profiles. Associations with body mass index and renal function were also examined. Results Roche p-tau217 showed high diagnostic accuracy for amyloid β (Aβ) positivity (AUC 0.973). In the primary threshold-analysis cohort, a dual-cutoff approach using thresholds of 0.225 and 0.336 pg/mL classified 88.1% of participants into definitive negative or positive zones, with an overall percent agreement of 95.0% within these zones. Sensitivity analyses showed similar performance. In participants with complete biomarker profiles, no statistically significant difference in AUC was detected between Roche p-tau217 and Simoa p-tau217, whereas Roche p-tau217 showed significantly higher AUC than p-tau181 and NfL. Lower estimated glomerular filtration rate (eGFR) was independently associated with higher p-tau217 concentrations. Conclusions Fully automated Roche p-tau217 showed high diagnostic performance for identifying Aβ pathology. Cohort-derived dual decision thresholds classified most participants into definitive zones and may support plasma p-tau217-based triage for confirmatory amyloid testing in memory-clinic practice. External validation is required before clinical implementation.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JFJong‐Ling Fuh
Jong‐Ling Fuh
CCChun‐Yu Chen
Chun‐Yu Chen
YLYung‐Shuan Lin
Yung‐Shuan Lin
Wei-Ju LeeWei-Ju Lee
Wei-Ju Lee
AYAlbert Yang
Albert Yang
Background: Two common variants of sortilin‐related receptor 1 gene (SORL1), rs2298813 and rs1784933, have been associated with late‐onset Alzheimer’s disease (AD) in the Han Chinese population in Taiwan. However, neuroimaging correlates of these two SORL1 variants remain unknown. We aimed to determine whether the two SORL1 polymorphisms were associated with any volumetric differences in brain regions in AD patients.Methods: We recruited 200 patients with late‐onset AD from Taipei Veterans General Hospital. All patients received a structural magnetic resonance imaging brain scan and completed a battery of neurocognitive tests at enrollment. We followed up to assess changes in Mini‐Mental State Examination (MMSE) scores in 155 patients (77.5%) at an interval of 2 years. Volumetric measures and cortical thickness of various brain regions were performed using FreeSurfer. Regression analysis controlled for apolipoprotein E status. Multiple comparisons were corrected for using the false discovery rate.Result: The rs2298813 and rs1783933 genotypes were not associated with cognitive test performance or clinical progression. The homozygous major allele of rs2298813 was associated with larger volumes in the right putamen (p = 0.0442) and right pallidum (p = 0.0346). There was no link of the rs1784933 genotypes with any of the imaging measures. In the rs2298813 homozygous major allele carriers, the right putaminal volume was associated with verbal fluency (p = 0.008) and clinical progression (p = 0.020). In the minor allele carriers, the right putaminal and right pallidal volumes were not significantly related to cognitive test scores or clinical progression.Conclusion: The major and minor alleles of rs2298813 had differential effects on the right lentiform nucleus volume and distinctively modulated the association between the regional volume and cognitive function.